Fifth Annual Biomedical Forum

Innovation and Global Collaboration in Biotechnology and Medical Devices

April 24, 2010 McDonnell Douglas Auditorium University of California, Irvine

www.SABPA.org

Editor: Hengchu Cao and Fred Ouyang

Printing: Bin Tian

© SABPA OC/LA

April 24, 2010

5th Annual Biomedical Forum April 24, 2010

Welcome to the 5th Annual Biomedical Forum. This year’s program will focus on the latest innovations in medical devices and biotechnology/ pharmaceutical industries, as well as business opportunities to thrive in the new economy amid global financial challenges. The mission of this forum is to provide an attractive platform for entrepreneurs, scientists, engineers, investors, executives, and policy makers to promote life sciences, biotechnology, pharmaceutical, medical device and alliances across the biomedical industry in Southern California and Asia. The annual biomedical forum is one of the flagship events organized by SABPA OC/LA, which consistently attracted more than 200 attendees. This year, we have brought to you pioneers and renowned innovators in the field, as well as exhilarating entrepreneurs that help accelerate the development of technology into clinical practices. Furthermore, we will introduce two Special Reports from China to join the discussion on reviving the economy from global collaboration perspective. I hope you will enjoy the program.

Hengchu Cao, PhD President, SABPA OC/LA

Program 8:00 am Registration

Coffee and Breakfast 8:15 am Opening Remarks

Hengchu Cao, PhD, President, SABPA OC/LA Matthew Jenusaitis, MBA, President and CEO, OCTANe "CA Medical Devices and the Importance of a Robust International Strategy"

Session I Global Trends in Biotech and Pharmaceutical Industry Moderator: Alex Qiu, MD, PhD, Allergan, Inc

8:45 am Philip Schwartz, PhD, Director, National Human Neural Stem Cell Resource, Children's Hospital of Orange County Research Institute “Human Neural Stem Cells for Therapy and Gene Discovery”

9:15 am Ji Li, PhD, Director, External R&D Affairs, Amgen Inc. “Partnering Approach at Amgen”

9:45 am William Martin, PhD, Laboratory Director, PRL-SW, US FDA “Adulteration in the Foods, Dietary Supplement/Herbal Products and Medical Products Industries: Domestic and Import Observations and the Quality Challenges to Industries”

10:15 am Coffee Break

Session II Innovation in Medical Device Industry

Moderator: Shouyan Lee, PhD, Medical Implant Mechanics 11:00 am Sanjay Shrivastava, PhD, Director, Research &

Development, EV3 Neurovascular, Inc “Materials and Design Considerations in Endovascular Treatments of Ischemic Stroke and Cerebral Aneurysms”

11:30 am K. T. Rao, PhD, Chief Scientific Officer and Vice President, Nellix Endovascular Inc. “Fillable Endovascular Aneurysm Treatment”

12:00 pm Lunch and Visit Exhibit Booth

Session III Global Operation Strategies Moderator: Scott Lopez, Biotronik, Inc.

1:00 pm

Fidela Moreno, MD, VP, Global Development Operations/ Clinical Site Management and Monitoring, Allergan Inc. “The Globalization of Clinical Trials: Opportunities and Challenges for the Asia Pacific Region”

1:20 pm Sabing Lee, JD, Knobbe, Martens, Olson & Bear, LLP " Best Practices for Protecting Your Technology and IP in the U.S. and China”

1:40 pm

Paul A. DeRidder, MD, MBA, Venture Partner-Crystal Cove Capital, Partner-Ampleluck International Capital Group, Ltd "China Angel Investment: A New Beginning"

2:00 pm James Jiayuan Tong, MD, PhD, Chief Financial Officer, Chief Business Development Officer Tianyin Pharmaceutical Co. “China BioMedical, PIPE's, M&A and other Exit Strategies”

2:20 pm Break

Session IV Global Economic Collaboration:

Moderator : John Shu, JD, Stradling Yocca Carlson & Rauth

2:40 pm Andrew Pan, North America Representative Office of Shenzhen, China “Shenzhen-China's City of Innovation and Entrepreneurship--Update, Opportunities and Case Study in Biotechnology Industry”

3:00 pm Steve Jia, PhD, Co-founder and President , PacificBio Inc. & CTO, Shenyang US Cal Biomed Co LTD “Introduction of Shenyang International Biology Park”

3:20 pm John Shu, JD, Stradling Yocca Carlson & Rauth “The Foreign Corrupt Practices Act: Special Watchpoints for Bio/Pharmaceutical Companies Operating in China”

3:40 pm Closing Remarks Peter Chen, PhD, President, Center for Innovation and Strategic Collaboration, St. Jude Medical, Inc.

3:50 pm Reception and Social Hour

Speaker Biographies

Hengchu Cao, Ph.D. Director of Engineering Edwards Lifesciences President, SABPA OC/LA Dr. Hengchu Cao has over 20 years of work experience, with 16 years in class III implantable medical devices. He has a strong technical and scientific background, especially in computer

modeling (FEA/CFD), materials development (biocompatible metals, polymers and ceramics), fatigue life analysis, reliability, device testing, design and analysis. He has strong technical leadership skills in managing R&D project teams. He has extensive experience in supporting product regulatory approvals worldwide. Dr. Cao devotes considerable effort to promote the technical excellence in biotech and biomedical engineering profession in the southern California region. He took part in the inaugural biotech and medical device forum by the SABPA OC/LA chapter and co-Chaired the second Biomedical Forum. He is elected Board of Directors for SABPA and serves as the current president for the Orange County/Los Angeles Chapter. Dr. Cao has co-chaired the Annual ASME Frontiers in Biomedical Devices Conference and Exhibition in 2008. He holds a BS in chemical engineering from South China University of Technology, and a PhD in materials science from University of California at Berkeley. Dr. Cao has over 30 technical publications and holds several patents in innovative medical devices. He was named in the American Men and Women of Sciences.

Matthew Jenusaitis, MBA President and CEO, OCTANe Matthew Jenusaitis is the President and CEO of OCTANe, an Orange County, CA non-profit organization focused on catalyzing innovation, starting new medical and high technology companies, and creating jobs. Matthew is an experienced medical device industry professional with more than 25 years of engineering, sales and marketing, and executive level general

management experience. Before OCTANe, Mr. Jenusaitis worked with the venture backed accelerator fund, ConcepTx, identifying unmet clinical opportunities and developing new technologies and companies. Prior to ConcepTx, Matthew was and executive in residence for the private equity firm Warburg Pincus, LLC. This led to Matthew assuming the role of President of ev3 Neurovasuclar, one of Warburg’s portfolio companies.

Prior to ev3, Matthew spent 15 years at Boston Scientific Corp., where he served in numerous executive marketing and general management positions. During his career, Matthew also spent 8 years at Baxter healthcare in both marketing and engineering management positions.

Matthew is the Chairman of the Board of Directors for Avantis Medical in Sunnyvale, CA, and sits on the boards of Neuro Interventional Therapeutics in Pittsburgh, PA and Creagh Medical in Galway, Ireland. He also sits on the advisory boards for Cornell’s School of Biomedical Engineering, the Keck Graduate Institute of Applied Life Sciences, and the University of California Bren School of Information and Computer Science.

Jenusaitis holds a bachelor of science in chemical engineering cum laude from Cornell University, a master of science in bio-chemical engineering from Arizona State University and a master of business administration from University of California, Irvine.

Alex Qiu, M.D. Ph.D. Allergan, Inc. SABPA Board Member

Graduated from Jiangxi Medical College with clinical practice and research experience in the late 80's, Alex came to the US for further education. In 1997, he obtained Ph.D. in Biochemistry in the Bowan Gray School of Medicine, Wake Forest University. From 1997 to 2001, Dr Qiu did postdoctoral

research in Howard Huges investigator Dr.Y.W. Kan 's lab, initially in the gene therapy area, later turned to the obesity study under Dr. Farid Chehab. Developed first letpin transgenic mice under fat promoter, and became a front runner in the field to understand how leptin regulates body weight and energy homeostasis. In 2001, started industrial career under legendary scientist Dr.Flossie Wong-Staal, who identified HIV virus and start her own company using cutting edge technology of ribozyme derived gene knockdown strategy to identify drug targets. In 2002 to now, work in GPCR specialized company Arena Pharmaceuticals, identified several important orphan GPCRs to treat

metabolic disorders, 3 patents have been filed based on my research. From 2007 to present, turned interests to the clinical development, from regulatory filing, to clinical study design and execution. Served as clinical consultant in Conventus Biomedical Inc and principal scientist in clinical pharmacology in Allergan Pharmaceutical Inc.

Philip H. Schwartz, Ph.D., Director, National Human Neural Stem Cell Resource, Children's Hospital of Orange County Research Institute Trained at UCLA's Brain Research Institute, Dr. Schwartz is a full-time stem cell biologist and holds a Senior Scientist position at the Children's Hospital of Orange County (CHOC) Research

Institute. Dr. Schwartz is Director and Founder of CHOC's National Human Neural Stem Cell Resource (NHNSCR), an Associate Research Biologist at the University of California, Irvine (UCI), Developmental Biology Center, and a Visiting Associate Professor in the Stem Cells and Regeneration Program of the Burnham Institute. A Principal Investigator of one of the NIH's 5 T15 Human Embryonic Stem Cell Culture Training Courses, Dr. Schwartz trains national and international scientists in current human embryonic and neural stem cell techniques. Dr. Schwartz regularly participates in special study sections on stem cells at the NIH. As part of the NHNSCR, Dr. Schwartz maintains clinical collaborations with several west Coast university hospitals and has active research collaborations with over 30 national and international stem cell researchers. Dr. Schwartz also regularly disseminates stem cell research information to the lay public by way of the print, television, and radio media. Dr. Schwartz' current organizational efforts have been to establish the Center for Stem Cell Transplantation at CHOC and the Stem Cell Research Center at UCI, in addition to fostering formal collaborative efforts between CHOC and UCI in stem cell research. Dr. Schwartz sits on the CHOC Ethics Committee and IACUC and is currently funded by the CHOC Foundation for Children and by the National Institutes of Health. brains from patients that have died with neurogenetic disease and the research in his laboratory is directed towards understanding the factors influencing the behavior of human central nervous system (CNS) stem cells and multipotent CNS progenitor populations in the normal and neurogenetically diseased brain.

Ji Li, Ph.D. Director of External R&D Affairs, Amgen Inc. Dr. Ji Li is currently Director of External R&D Affairs at Amgen where he is responsible for the sourcing and evaluation of worldwide in-licensing and M&A opportunities in several therapeutic areas, including Metabolic Diseases (bone, diabetes, nephrology, cardiovascular and

muscular disorders), Hematology and oncology supportive care, and Neuroscience. Prior to his current role in business development, Ji worked as a scientist in bone and inflammation research at Amgen. He was member of the research team that discovered and validated the critical OPG-RANKL-RANK signaling pathway in osteoclast bone cells. This major breakthrough in bone biology has since led to the development of Denosumab, which is currently pending for FDA approval in the treatment of various bone loss conditions, such as osteoporosis and cancer bone metastases. Ji received his PhD in Neuroscience from Mount Sinai School of Medicine in New York, and his BS in Pharmacology from Shanghai Medical University in China.

William B. Martin, Ph.D. Director, Pacific Regional Laboratory – Southwest United States Food and Drug Administration William B. Martin, Ph. D., Director, Pacific Regional Laboratory – Southwest has been with the FDA for 13 years. As Director, Dr. Martin provides executive and scientific leadership to the third largest Regional Laboratory within FDA’s Office of Regulatory Affairs. Dr. Martin holds B. S. and Ph.

D. degrees in Chemistry from the University of South Florida in Tampa, Florida and performed a Post-doctoral Fellowship at the National Science Foundation’s Middle Atlantic Mass Spectrometry Facility at the Johns Hopkins University School of Medicine in Baltimore, Maryland. He came to FDA from the aerospace industry where he was a Senior

Materials & Process Engineer for Honeywell Space & Strategic Systems Operations. Dr. Martin was a regulatory mass spectrometry specialist where he developed and performed analytical methods using mass spectrometry in the analysis of trace residues in tissues, foods and drugs. He is a graduate of the 2002 FDA Executive Leadership Development Program and assumed the leadership role for the Pacific Regional Laboratory Southwest in 2005.

Dr. Martin serves as a facilitator of several FDA scientific and management working groups and serves on the Office of Regulatory Affairs Field Drug Committee as the Pacific Region representative. Dr. Martin attempts to open lines of communication between the federal government and the community through outreach and collaborative activities with shared interest stakeholders.

Shouyan Lee, Ph.D. President, Suzhou Albert Biomedical Engineering CSO, Medical Implant Mechanics LLC Dr. Lee is a graduate of Tsinghua University in Beijing, China with a bachelor’s degree in engineering mechanics and master’s degree in

biomedical engineering, and University of California, San Diego, with a Ph.D. in biomedical engineering.

Dr. Lee has been a biomedical engineering professional since 1985. He had started research on prosthetic heart valves with testing Carpentier-Edwards valve in 1982. He taught at Tsinghua University from 1985 to 1987. After receiving Ph.D. in 1993, Dr. Lee had held several key R&D positions at Carbomedics, Cardiomedical Solutions, VIASYS Healthcare (a Cardinal Health company) and Arbor Surgical Technologies. He was responsible in the development of two tissue prosthetic heart valves, two critical care ventilators and two minimally-invasive cardiovascular surgical devices. Dr. Lee has extensive experience in medical device product research and development, especially in research and development of tissue prosthetic heart valves. He has successfully taken three products from conception to production.

Dr. Lee is also the founder of Angel Heart International, Inc., a non-profit organization helping children with congenital heart defects.

Sanjay Shrivastava, Ph.D. Director, Research & Development, EV3 Neurovascular, Inc Dr. Sanjay Shrivastava is a director of research & development at the Neurovascular division of ev3, Inc. In his current role, he is responsible for developing products for ischemic stroke, aneurysm bridging, and neurovascular flow diversion. Much

of Dr. Shrivastava’s career has been focused at developing cardiovascular medical devices including coronary and peripheral drug eluting stents, bare metal self expanding and balloon expandable stents, vena cava filter, heart valve, and AAA stent-graft. He is a named inventor on more than 20 issued or filed US patents. He has been invited speakers at many clinical and engineering conferences and is the editor of a book titled “Medical Device Materials”. Shrivastava played a key role in starting “Materials and Processes of Medical Devices” under the auspices of ASM International for which he was the conference chair in 2003. Medical Device & Diagnostic Industry listed him among 100 Notable People in the Medical Device Industry in 2004. Prior to joining ev3, Inc., Shrivastava worked at Abbott Vascular and Edwards Lifesciences, Inc. in the area of product development. Shrivastava holds a doctorate degree in materials science & engineering from the University of Florida.

K. T. Rao, Ph.D. Chief Scientific Officer and Vice President Nellix Endovascular, Palo Alto, CA Dr. Rao is Chief Scientific Officer and Vice President of R&D at Nellix Endovascular, developing a novel, minimally-invasive platform for the treatment of aneurysms. Previously with J&J (Cordis, NDC) and Guidant, KT has been involved with the design, development, regulatory approvals

and market launch of several medical devices including coronary, carotid, peripheral and neurovascular stents, embolic filters and aortic stent-grafts. Notable accomplishments include the introduction of Multi-

Link Vision, a new cobalt-chromium stent along and developing a strong technology portfolio that established Guidant’s sustained leadership in coronary stents. KT holds a BTech, MS, and PhD in Materials Science from Indian Institute of Technology at Madras, Purdue and University of California at Berkeley.

Scott Lopez, MBA Medical Device Sales and Marketing Orange County and Inland Empire Southern California, Biotronik, Inc.

Mr. Lopez is responsible for sales and marketing of the Biotronik Cardiac Rhythm Management product line within South Orange County, Riverside and Temecula, CA. As a clinical advisor and technical

specialist, Mr. Lopez also attends device implant procedures at hospital cardiac catherization labs and operating rooms. Responsibilities include case flow, programming and troubleshooting pacemakers, implantable cardiodefibrillators and heart failure devices.

Pursuing his passion for International business and trade, Mr. Lopez also works to connect Southern California biomed and healthcare firms with overseas partners. International transactions include: joint venture, trade promotion, distribution and import / export activities.

Prior to joining Biotronik, Inc. Mr. Lopez was an officer in the United States Marine Corps for 10 years and served as an F/A-18 pilot and Public Affairs Officer in Southern California and the Middle East. His corporate sales career includes working for Boston Scientific, EchoStar and Starz Encore Group. He has been a successful business owner.

Fidela Llorca Moreno, M.D. Vice President Global Development Operations Global Clinical Site Management and Monitoring Allergan Inc.

In her current role, Fidela is responsible for the oversight of clinical site management and monitoring for Allergan’s global clinical trials in

North & South America, Europe/Africa-Middle East and Asia Pacific.

She joined Allergan in September 2008, following a successful 12-year career in pharmaceutical medicine at Pfizer in Connecticut, a 3-year Biotech career at Amgen in California, and an 8-year academic career as Assistant Professor of Medicine at the University of Utah, School of Medicine, in Salt Lake City, Utah, U.S.A. While in academia, she has more than 80 publications to her name, mostly in first line international medical journals.

Fidela is the recipient of 8 awards in research and medicine, and several other distinctions. The most recent of these are: the THOMAS Award for Excellence in Research given by the University of Santo Tomas in 1998, and the Award for Most Outstanding Alumni in the Field of Research, given by the VA Hospital in 2005. And in March 2008, she was named by the Utah Asian Chamber of Commerce as Most Outstanding Asian-American Professional of 2008.

She is very actively involved in community service, with her most recent contributions being: serving as an Organization Effectiveness Facilitator for the Office of the Governor of Utah, Office of Ethnic Affairs and Asian Advisory Council, and sitting as a member of the Board of Directors for the Los Angeles-based Kultura Philippine Folk Arts.

Fidela completed her medical education at the University of Santo Tomas in Manila, Philippines, her Residency in Internal Medicine at the V.A. Hospital, Fellowship in Adult Cardiology at the Philippine Heart Center for Asia, and Fellowship in Noninvasive Cardiology at the University of Utah and LDS Hospital in Salt Lake City, USA.

Sabing H. Lee, J.D. Knobbe, Martens, Olson & Bear, LLP

Sabing H. Lee is a partner in the Orange County office of Knobbe, Martens, Olson & Bear, LLP. Mr. Lee received his Bachelors Degree in Materials Engineering, Phi Beta Kappa and summa cum laude, from UCLA, and also received

his Masters Degree in Materials Science and Engineering from UCLA. He received his J.D. from the University of California, Berkeley School of Law (Boalt Hall), where he was an Articles Editor and Executive Editor for the Berkeley Technology Law Journal. Mr. Lee’s practice includes strategic patent procurement, patent portfolio management, general

counseling on infringement and licensing, interferences, reexaminations, and other related issues. Mr. Lee currently represents clients in a wide range of technologies, including medical devices, nanotechnology, and semiconductor fabrication.

Mr. Lee joined the firm in 1997 and became a partner in 2003. He was named as one of Southern California’s “Rising Stars” in intellectual property law in a survey of his peers, published in Los Angeles magazine and Super Lawyers magazine, in 2004, 2005, 2006 and 2007. In the medical device field, Mr. Lee has worked extensively with cardiovascular, orthopedic and aesthetic technologies. He has been involved in the intellectual property strategy and acquisitions of PercuSurge, Inc. (acquired by Medtronic, Inc.), Flex-Foot, Inc. (acquired by Össur hf.) and Endius, Inc. (acquired by Zimmer Holdings, Inc.).

Paul A. DeRidder, M.D., MBA Venture Partner, Crystal Cove Capital, LLC; Executive Committee, TCA Dr. Paul DeRidder is a venture partner at Crystal Cove Capital, LLC and an Executive Committee member for Tech Coast Angels. Dr. DeRidder is a board-certified urologist, receiving his medical training at the University of Michigan School of

Medicine. He was in private clinical practice for twenty-two years, and is a past Assistant Clinical Professor of Urology in the Department of Surgery at University of California, Irvine. Dr. DeRidder is a Diplomate of The American College of Physician Executives. He has been co-founder and CEO of several specialty management organizations, and was a co-founder and board member of Urotherapies, Inc., a nationally based single specialty management group dedicated to the enhancement of Urologic specialty care. Dr. DeRidder holds several patents on various medical devices. Dr. DeRidder was a charter member of the University of California, Irvine’s Healthcare Executive MBA program, and completed his MBA in November 1997. He is a Charter Member of the Executive Committee of the Deans Leadership Group at the University of California, Irvine, Paul Merage School of Business.

James Jiayuan Tong, MD, Ph.D., Chief Financial Officer, Chief Business Development Officer Tianyin Pharmaceutical Co.

Dr. Tong recently accepted a position as Chief Financial Officer, Chief Business & Development Officer Tianyin Pharmaceutical Co., Inc.. Dr. Tong is a past Vice President of Roth Investment Banking, with a focus on Healthcare industry in China. He joined ROTH Capital Partners Equity Research Department in early 2008 as a Research Analyst, covering Healthcare sector in China. Prior to joining ROTH, Dr. Tong was a Biotechnology analyst at Rodman & Renshaw in New York, covering small to mid cap biotech firms that are finding cures for Alzheimer’s disease, multiple sclerosis, cancers and developing diagnostic tools. Before the Wall Street career, Dr. Tong has been a Principle Investigator at Marine Biological Laboratory (MBL) sponsored by Grass Foundation at Woods Hole, MA and a senior research fellow at University of California, Irvine (UCI). Dr. Tong was awarded Ph.D. in Neurobiology and Behavior from Cold Spring Harbor Laboratory / Stony Brook University Neurobiology and Behavior joint program. During his years at UCI, he developed an innovative method to significantly extend life spans of the animals based on his research on mitochondria, aging and learning/memory disorders in Neurofibromatosis-1 (NF1) disease. His contribution to the understanding NF1 disease and longevity were published in three Nature articles. He currently holds two patents. Dr. Tong also has a M.D. from Peking University Health Science Center.

John Shu, JD Attorney, Stradling Yocca Carlson & Rauth John Shu is an attorney with Stradling Yocca Carlson & Rauth in Newport Beach, California. Mr. Shu served as a law clerk to the Honorable Paul H. Roney, U.S. Court of Appeals for the 11th Circuit, and as a judicial extern to the Honorable Stanley

Sporkin, U.S. District Court for the District of Columbia. Mr. Shu served in the White House under President George H.W. Bush and in Bush/Cheney Transition Headquarters under President-elect George W.

Bush. Mr. Shu has lived and studied in Asia, and has spoken on a number of legal, bio-technology, political, international relations, and foreign policy issues. Mr. Shu is a Term Member of the Council on Foreign Relations, a Member of the Foreign Policy Association, the National Committee on U.S.-China Relations, and the Pacific Council on International Policy. Mr. Shu has a B.A. from the University of Pennsylvania, a G.C. from Peking University, and J.D. from Pepperdine University.

Andrew M. Pan Chief Representative and Managing Director

North American Representative Office of Shenzhen, P. R. China (NAROS)

Andrew M. Pan is the primary official contact of the City of Shenzhen in North America and oversees the daily operation of Los Angeles based NAROS which

is a bilateral trade and investment promotion office of Shenzhen that gives support and free services for North American companies to do business in Shenzhen and other parts of China, as well as for Shenzhen companies to do business in the North America.

With his years of experience both in China and the U.S., Mr. Pan is a seasoned consultant on market entry, business development, sourcing and outsourcing, as well as government relations for overseas companies to do business in China and for China based companies to develop “Go Global” strategies.

Prior to NAROS, Mr. Pan served as the director of Foreign Investment Promotion of Shenzhen Bureau of Trade and Industry (SZBTI), the director of Economic Development of Shenzhen Free Trade Zone Administration (SZFTZ), and the senior manager of Shenzhen Foreign Investment Service Center (SZFIS).

Mr. Pan received a master of economics from Shanghai University of Economics and Finance and a bachelor of economics from University of International Relations, Beijing.

Steve Jia, Ph.D. Co-founder and President , PacificBio Inc CTO, Shenyang US Cal Biomed Co LTD

Dr. Jia is the Co-founder and President of PacificBio Inc, a California based biotechnology contract research organization for global biomedical and bio-fuel development. Dr. Jia is also the CTO of Shenyang

US Cal Biomed Co LTD. Dr. Jia has nearly 19 years of scientific research and management experience in the U.S. pharmaceutical, chemical and medical diagnostic industries. He has served as a laboratory director at Merck and DuPont Pharmaceuticals, specializing in drug R & D, and at Quest Diagnostics, specializing in molecular diagnostic product development and management. Dr. Jia also assists and participates in five biotech related ventures, three of which are located in China. His responsibilities include venture initiation, strategic planning, technology consulting and market development.

Dr. Jia received his Ph.D. in Biochemistry from Michigan Sate University and B.S in Genetics from Pecking University in China.

Peter C. Chen, Ph.D. President, Center for Innovation and Strategic Collaboration, St. Jude Medical, Inc. Peter C. Chen, Ph.D., is the Founder of Irvine Biomedical , Inc. ( IBI), a ST. Jude Medical Company. He has been with the company since its inception in January 1995, and is responsible for fund-raising, new

product developments, goal setting and establishing the infrastructure of the Company. Since the formation of Irvine Biomedical, Inc., he has successfully led the Company to develop, launch, and market electrophysiology products around the world. He was able to grow IBI into a million dollar company before being acquired by St. Jude Medical, a multi-billion global medical device company, in October of 2004. After the acquisition, Dr. Chen continued his position as the President of IBI, responsible for all the day-to-day operation. Dr. Chen’s unique background in engineering and product development has enabled him to launch new and innovative products which have helped the IBI business to grow 33% annually to generate a sales revenue over $100 millions in 2008. He has more than 25 years experience in the medical device industry, specifically in the design and development of medical instrumentation.

Dr. Chen is well known in the field of Electrophysiology and Cardiac Rhythm Management through his innovative invention of new devices for treating cardiac arrhythmias. He is the author and co-author of more than 15 patents and 20 publications. Recently, Dr. Chen has been named as the President of a newly created division of St. Jude Medical; Center for Innovation and Strategic Collaboration. Dr. Chen is a graduate of University of Kansas with a Master degree in Electrical Engineering, and the State University of New Jersey, Rutgers, with a Ph.D. Degree in Biomedical Engineering. Prior to founding IBI, Dr. Chen held several key R & D positions in some of the major medical device companies including Baxter Health Care, Guidant Corp, and Johnson & Johnson. Dr. Chen was named in the 2006-2007 Strathmore’s WHO’s Who. He was named as Honorary Chairman, Business Advisory Council of The National Republic Congressional Committee in 2003 and 2007.

Sponsors Description

St. Jude Medical is dedicated to developing medical technology and services that put more control in the hands of physicians, and that advance the practice of medicine and contribute to successful outcomes for every patient. We strive for continuous improvement in everything we do, every day. We are committed to consistently meeting the highest quality standards and operating in a highly disciplined environment, backed by rigorous business ethics. It is our mission to develop medical technology and services that put more control into the hands of those who treat cardiac, neurological and chronic pain patients, worldwide. We do this because we are dedicated to advancing the practice of medicine by reducing risk wherever possible and contributing to successful outcomes for every patient. For more information, please visit ://www.sjm.com. Knobbe Martens Olson & Bear LLP, currently the third largest IP firm nationwide, is a law firm practicing exclusively in the area of intellectual property law including patents, trademarks, copyrights, trade secrets, rights of publicity, unfair competition, and related litigation and licensing. The firm maintains offices in Orange County, San Diego, San Francisco, Los Angeles, Riverside, Washington D.C., and Seattle. Services are provided to clients throughout the United States and the world. At present, the firm is composed of more than 250 lawyers and other professionals, nearly all of whom hold undergraduate or graduate degrees in either engineering or the technical sciences. This combination of law and technology makes Knobbe Martens uniquely qualified to represent a diverse array of clients in a broad spectrum of intellectual property matters. For more information, please visit ://www.kmob.com/. Hantel was founded in 1999 by Mary and Dave Gallup. Their vision of a company that would bring medical devices to market, with all services provided under one roof, laid the groundwork for building the comprehensive service provider that Hantel is today. Their mission was to create a company culture and structure that facilitated rapid project turnaround, and provided the flexibility in service needed to meet the unique needs of an extremely diverse clientele, from startups to fortune 500 companies. Since then, Hantel has become a leader in contract design and manufacturing, having developed hundreds of products for a wide array of applications. Hantel retains a highly qualified and diverse workforce with expertise in all aspects of medical device development and manufacturing. Located near the heart of Silicon Valley and near several major universities, Hantel is convenient and accessible to a wide array of device and biotech firms. Providing fast and flexible service,

Hantel was built to meet your needs. For more information, please visit: .hanteltech.com . Agilent is a leading supplier of life science instrumentation and reagents. Several acquisitions have even further broadened the product portfolio and today, Agilent liquid and gas chromatography systems, mass spectrometers, DNA microarrays and scanners, thermal cyclers, automation instruments, reagents and software are used globally. Agilent has aggressively developed products and services utilized along the entire discovery value chain, from basic biological research through drug discovery and manufacturing, making life science tools Agilent’s fastest growing category. This commitment to innovation has made the company a major factor in the emerging trend of “systems biology,” where scientists are beginning to make inroads against important diseases by examining them from multiple perspectives. Agilent tools help scientists to understand complex biological processes, unlock the causes of disease and speed the discovery of new drugs. Agilent provides products throughout the entire pharmaceutical value chain from basic research to drug manufacturing quality control. For more information, please visit: ://www. agilent.com/

Bose Corporation’s ElectroForce Systems Group manufactures ElectroForce® test instruments using proprietary linear motor technology. Bose offers instruments for the characterization of soft tissues, bones, biomaterials, and a variety of medical devices. The ElectroForce BioDynamic® test instrument provides characterization and stimulation of tissue constructs in a biological environment. For more information, please visit: .bose-electroforce.com . China Medical City TaiZhou located on a 25-square kilometer site in the heart of Taizhou City in China's Jiangsu Province. China Medical City was established by the Chinese Government in 2005 and has active support from the local government. China Medical City is positioning itself to become the country’s largest pharmaceutical, biotech, and medical equipment development zone, with cutting-edge support service and streamlined regulatory and registration processes. The city of Taizhou is fast becoming Jiangsu's leading biotech location, with over 35% annual growth since 2004. At the moment, the park is home to over 50 renowned universities and medicine research institutions at home and abroad, more than 200 enterprises engaged in medicine manufacturing and services, and more than 200 innovation achievements with relatively high level has been yielded. In March 2009, approved by the State Council, the Taizhou Medical Hi-tech Development Zone was turned into the only national hi-tech development zone of its kind and encapsulated in the state innovation system. Considered a prime area for growth and

stability, China Medical City is located on the Yangtze River only two hours from Nanjing and three hours from Shanghai. Medical Implant Mechanics LLC. provide customers most advanced, highest quality and timely mechanics solutions and services both analytically and experimentally. Medical Implant Mechanics has solid records to help our clients to realize thier ideas into products or to obtain regulatory approvals in timely fashion, call us for your R&D and regulatory need today. Medical Implant Mechanics offers Structural Finite Element Analysis (FEA), Computational Fluid Dynamics (CFD), and Customized Mechanical Testing on implantable medical devices including Stents, Filters, Stented Grafts, Heart Valves, Transcatheter Valves and Orthopedics Products. As new decade starts, Medical Implant Mechanics is pleased to extend services to include material processing consulting, translations between English and Chinese and OEM identification in China. For more information, please visit ://www.medicalimplantmech.com/home . Suzhou Albert Biomedical Engineering, Ltd was founded in August, 2008 in Suzhou Industrial Park, China, ABE is a research and development laboratory aiming to reduce the risk and cost for the most difficult first phase for entrepreneurs in medical device product development. Utilizing the talent pool and manufacturing base in China, ABE is able to help customers with much reduced cost ranging from analysis, testing, drafting services to prototype development and eventually OEM setup. Currently, ABE has developed a portable heart valve prostheses tester which can be used to perform accelerated wear testing (AWT) and pulsatile flow testing on the same tester. ABE is also working on several product concepts and undertaking a few product developments/testing contracts in both cardiovascular and respiratory care area. MTS Systems Corporation is a global supplier of test systems and industrial position sensors. The Company operates in two segments: the Test segment and the Sensors segment. Test segment products are used by customers in their development of new products and in quality control applications to characterize the product’s mechanical properties. Sensors segment products are used by industrial machinery and mobile equipment manufacturers to automate the operation of their products for end user productivity and safety. For more information, please visit: .mts.com . North American Representative Office of Shenzhen, P. R. China (NAROS) is a U.S. based free business service provider representing

the City of Shenzhen, the first Special Economic Zone in China, and the biggest import and export city among all mainland China cities. Sponsored by the Municipal Government of Shenzhen and the Shenzhen Bureau of Trade and Industry (SZBTI), NAROS gives free support and services for all North American companies interested in business in Shenzhen and other parts of China. NAROS also supports and services Shenzhen companies interested in North America. For more information, please visit http://www.shenzhenoffice.org/ . Shenyang US California Biomed Co., Ltd. Shenyang USC Biomed Co., Ltd. devotes to specially build public service platform, which is called Liaoning International Joint Biotech Research Institute and the Shenyang International Bio-industrial Park, and is mainly guided by the government. The main aim of the company should be promoting achievements conversion of the chain of biotechnology industry. The company provides service not only for scientists and entrepreneurs, but also for the investors and governments; to help scientists promoting industrialization of biotechnology innovation achievement; for entrepreneurs to provide the achievement with value of industrialization and industrial incubator ;to help investors shorten the investment cycle, reduce investment risks; to service for the government, integrated public services platform of Chinese biological resources, , to improve Chinese international competitiveness of new drugs independent research and development ; aim to promote large-scale, international growth, and become the industry leader in the listing and financing market. SIMULIA is the Dassault Systèmes brand that delivers a scalable portfolio of Realistic Simulation solutions including the Abaqus product suite for Unified Finite Element Analysis, multiphysics solutions for insight into challenging engineering problems, and SIMULIA SLM for managing simulation data, processes, and intellectual property. By building on established technology, respected quality, and superior customer service, SIMULIA makes realistic simulation an integral business practice that improves product performance, reduces physical prototypes, and drives innovation. Headquartered in Providence, RI, USA, SIMULIA provides sales, services, and support through a global network of regional offices and distributors. For more information, visit ://www.simulia.com .

Conference Organizing Committee

Function Committee Members

Program Editing Hengchu Cao, Fred Ouyang Program Printing Bin Tian Poster Printing Esmael Heidari Signs Printing Xinxin Wu Website Update Henry Li, Zhen Zhu Parking Coordination Yuanfeng Wang, Li Zhang, Jinmei Wang Attendee Book Keeping Xue Hua, Jun Zuo, Wei Du, Vivian, Xinxin Wu Food and Service Coordination Teresa Wong, Joy Liu, Xinxin Wu Conference Tech Service Coordination Goran Matijasevic, Chih Lew, Joy Liu Conference Setup and Cleanup (outside) Jerry Liu, Kelvin Shao, Zhen Zhu, Quanyin Gao, George Liu Sponsor Service Alex Qiu, Fred Ouyang Speaker Coordination Paul DeRidder, Hengchu Cao, Goran Matijasevic On-line Registration Vivian Chang, Xue Hua On-site Registration Bing Leng, Jiang Ying, Joy Yang, Shanshan Xu On-site computer Hengchu Cao, Fred Ouyang Gift Design and Purchase Joy Liu, Simon Han, Vivian Chang Photographer Jiang Ying, Yan-Bo Yang

For more information about membership and sponsorship, please contact :sabpa.ocla@gmail.com

Gold Sponsors

Silver Sponsors

Bronze Sponsors

UCBC

Event Sponsors

Media Sponsors

© SABPA OC/LA 2010